Kiora Pharmaceuticals (KPRX) Non-Current Assets (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Non-Current Assets came in at $2.5 million in Q1 2026, down 63.19% YoY from $6.9 million in Q1 2025, and up 1.57% on a QoQ basis from $2.5 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Non-Current Assets (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Non-Current Assets data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 63.19% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (down 34.21% YoY) and the FY2025 annual result came in at $2.5 million, down 63.05% from the prior year.
- Non-Current Assets rose to $2.5 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $11.1 million in Q1 2022 to a low of $2.5 million in Q4 2025.
- A 5-year average of $8.3 million and a median of $9.0 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets climbed 4.56% — and 2026, when it sank 63.19%.
- Tracing KPRX's Non-Current Assets over 5 years: stood at $11.0 million in 2022, then decreased by 18.4% to $9.0 million in 2023, then decreased by 24.46% to $6.8 million in 2024, then plunged by 63.05% to $2.5 million in 2025, then increased by 1.57% to $2.5 million in 2026.
- The last three Non-Current Assets figures came in at $2.5 million (Q1 2026), $2.5 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 2.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.51 Mn |
| Mar 31, 2026 | 2.54 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | 7.17 Mn |
| Jun 30, 2025 | 7.21 Mn |
| Mar 31, 2025 | 6.91 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | 6.86 Mn |
| Jun 30, 2024 | 8.98 Mn |
| Mar 31, 2024 | 8.96 Mn |
| Dec 31, 2023 | 8.97 Mn |
| Sep 30, 2023 | 8.91 Mn |
| Jun 30, 2023 | 10.86 Mn |
| Mar 31, 2023 | 10.91 Mn |
| Dec 31, 2022 | 11.00 Mn |
| Sep 30, 2022 | 11.04 Mn |
| Jun 30, 2022 | 11.08 Mn |
| Mar 31, 2022 | 11.09 Mn |
| Dec 31, 2021 | 11.14 Mn |
| Sep 30, 2021 | 13.62 Mn |